AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival
February 17, 2021Research and Development AstraZeneca, Cancer, MSD
The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …
Novartis and Gates Foundation join forces on sickle cell disease research
February 17, 2021Research and Development Novartis, sickle cell disease
Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …
FDA approves Novartis’ heart failure drug Entresto
February 17, 2021Research and Development FDA, Novartis
The FDA has approved Novartis’ Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalisation for heart failure in …
North Korea accused of attempted Pfizer hack to steal COVID-19 vaccine data
February 16, 2021Manufacturing and Production COVID, COVID Vaccine, COVID-19, North Korea, Pfizer, Pfizer vaccine, Vaccine
North Korea has tried to hack into Pfizer’s servers in order to ascertain its COVID-19 vaccine technology, according to a …
South Korea orders 46 million more Novavax and Pfizer COVID-19 vaccines
February 16, 2021Manufacturing and Production COVID, COVID-19, Novavax, Pfizer, Vaccine, south korea
South Korea has arranged deals with Novavax and Pfizer-BioNTech to buy enough COVID-19 vaccines for 23 million more people.
WHO approves two versions of AstraZeneca’s COVID-19 vaccine
February 16, 2021Manufacturing and Production AstraZeneca, COVID-19, WHO
The WHO has greenlighted two versions of the Oxford-AstraZeneca COVID-19 vaccine for emergency use, granting them authorisation to be rolled …
Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK
February 16, 2021Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …
Celltrion’s inflammatory disease drug Yuflyma gets EU approval for 13 indications
February 16, 2021Manufacturing and Production EC, celltrion
The European Commission (EC) has granted marketing authorisation for Celltrion’s Yuflyma, an adalimumab biosimilar, across all thirteen intended indications for …
University of Glasgow and Lilly sign £4.6m immunological disease partnership
February 15, 2021Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg
The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …
Pfizer COVID-19 vaccine proven 94% effective in biggest study yet
February 15, 2021Sales and Marketing COVID-19, Pfizer, Pfizer vaccine, Vaccine, coronavirus
The Pfizer-BioNTech COVID-19 vaccine has been proven to be 94% effective, according to the first major study to evaluate the …
AstraZeneca’s COVID-19 vaccine to be trialled in children
February 15, 2021Sales and Marketing AstraZeneca, COVID-19
The Oxford-AstraZeneca COVID-19 vaccine is to be tested on children in the UK in a new trial commencing this month. …
Genentech’s injectable eye medicine extends time between treatments for two conditions
February 15, 2021Sales and Marketing Genentech
Genentech has announced detailed, positive results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment …
Molecular Templates signs cancer deal with BMS worth up to $1.3bn
February 15, 2021Sales and Marketing Bristol-Myers Squibb, bristol myers squibb
Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth up to $1.3 billion, to …
Pharmafile.com’s top 10 news stories of the week
February 12, 2021Medical Communications
Over the past week, AstraZeneca’s COVID-19 jab has been at the centre of disputes about vaccine efficiency both in older …
NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use
February 12, 2021Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb
NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …
AstraZeneca COVID-19 vaccine still restricted, despite WHO assurances
February 12, 2021Medical Communications AstraZeneca, COVID-19
Several European countries have continued to impose age restrictions on their rollouts of the Oxford University-AstraZeneca vaccine, despite WHO’s repeated …
FDA approves Regeneron’s Evkeeza for HoFH
February 12, 2021Medical Communications FDA, Regeneron
The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …
Arthritis drug tocilizumab cuts COVID-19 deaths in hospital trial
February 12, 2021Medical Communications COVID-19
The rheumatoid arthritis drug tocilizumab can reduce the risk of death in severe COVID-19 patients and shorten the time spent …
Galapagos and Gilead halt Phase III trials for idiopathic pulmonary fibrosis drug
February 11, 2021Gilead
Galapagos and Gilead have halted the ISABELA Phase III clinical studies for their autotaxin inhibitor ziritaxestat in patients with idiopathic …
NICE recommends treatments for pregnancy sickness in new draft guidance
February 11, 2021NICE, Pregnant
NICE has recommended treatment options for severe pregnancy sickness for the first time, issuing recommendations in draft guidance published today.
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
